EUCTR2007-007945-11-BG进行中（未招募）不适用
A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery - SAVE-HIP2
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients can be included only if they satisfy the following inclusion criteria:
- •1. Standard surgery for fracture of the upper third of the femur, including femoral head and neck.
- •2. Signed written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria related to study methodology:
- •1. Legal lower age limitations (country specific)
- •2. Estimated time of injury/fracture >24 hours before admission to hospital
- •3. Time from injury/fracture to surgery >60 hours
- •4. Any major orthopedic surgery in the 3 months prior to study start
- •5.multiple trauma affecting more than one organ system
- •6. Clinical signs or symptoms of DVT or PE within the last 12 months or known post phlebitic syndrome
- •7. Known sensitivity to iodine or contrast dyes and any contra-indications to the performance of venography
- •8. Any treatment or procedure within 2 weeks prior to randomization or planned during the course of the study treatment period, that could affect the incidence of VTE, such as:
- •- Parenteral anticoagulants (UFH, LMWH [i.e. enoxaparin, dalteparin, nadroparin,...],
- •fondaparinux, bivalirudin, hirudin)
- •- Oral anticoagulants (vitamin K antagonists)
- •- GPIIb/IIIa antagonists: abciximab, eptifibatide, tirofiban
- •- Thrombolytic agents
- •- Dextrans
- •- Intermittent pneumatic compression of the legs (IPC)
- •Note: Chronic treatment with antiplatelet agents such as low-dose aspirin (up to 325 mg/day), clopidogrel or ticlopidine in patients with coronary artery disease is allowed
- •9. Known progressive malignant disease
- •10. Subject unlikely to comply with protocol, e.g. uncooperative attitude, inability to
- •return for follow-up visits, inability to receive daily injection (preferably by a nurse) after hospital discharge and unlikelihood of completing the study
- •11. Treatment with any investigational product or investigational device in the last 30 days or 5 half lives (whichever is longer, if relevant) prior to randomization
- •12. any previous exposure to AVE5026 (e.g participation in any previous AVE5026 clinical trial)
- •Exclusion criteria related to enoxaparin:
- •12. Active major bleeding
- •13. Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of enoxaparin sodium
- •14. Known hypersensitivity to enoxaparin sodium (e.g. pruritus, urticaria, anaphylactoid reactions)
- •15. Known hypersensitivity to heparin or pork products
- •16. Conditions with increased risk of hemorrhage, such as bacterial endocarditis, congenital or acquired bleeding disorders, active ulcerative and angiodysplastic gastrointestinal disease, hemorrhagic stroke, or shortly after brain, spinal, or ophtalmological surgery
- •Exclusion criteria related to AVE5026:
- •17. End stage renal disease (creatinine clearance <10 mL/min) or patient on dialysis
- •18. Pregnant or breast-feeding women
- •19. Women of childbearing potential not protected by highly effective contraceptive method of birth control as defined for contraception in the Informed Consent Form and/or who are unwilling or unable to be tested for pregnancy.
- •Pregnancy status should be checked by serum or urine pregnancy testing prior to exposure to the investigational product.
研究者
相似试验
进行中（未招募）
不适用
A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sclerosis (ALS).ALS-TAL-201-OL is added as an open label extension of the ALS-TAL-201 trial: A Multinational, Multicenter, Open label phase to Assess Tolerability and Safety of Talampanel 50mg tid in Subjects with Amyotrophic Lateral Sclerosis (ALS).EUCTR2008-002062-62-BETeva Pharmaceutical Industries, Ltd540
已完成
不适用
A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with placebo for the Extended Prevention of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery - SAVE-HIP3-I82I82PER-079-08sanofi-aventis Recherche & Development,
进行中（未招募）
不适用
A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery - SAVE-HIP2EUCTR2007-007945-11-DKsanofi-aventis recherche & développement1,000
进行中（未招募）
不适用
A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate for Injection in Subjects with Amyotrophic Lateral Scelorsis ALS - NDEarly stage subjects with probable, probable laboratory-supported or definite ALS according to the El Escorial criteria.MedDRA version: 6.1Level: PTClassification code 10002026EUCTR2006-001688-49-ITTeva Pharmaceutical Industries Ltd.300
进行中（未招募）
不适用
A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery - SAVE-HIP2The subjects who will participate to this clinical trial are patients undergoing Hip Fracture Surgery.MedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisEUCTR2007-007945-11-PTsanofi-aventis recherche & développement1,000